Previous 10 | Next 10 |
First half-year 202 2 financial results : Jyseleca ® net sales reached €35.4 million Group revenues of €274.0 million Operating loss of €97.5 million Cash and c ...
Galapagos ( NASDAQ: GLPG ) stock fell ~5% on July 25 after Jefferies Financial downgraded the stock to Underperform from Hold. The firm took the action citing challenges facing the Belgium company's base business and the challenges the biotech faces in rebuil...
Mechelen, Belgium-based biotech Galapagos (NASDAQ:GLPG) (OTC:GLPGF) has agreed to acquire CellPoint, a privately held developer of point-of-care CAR-T therapies and AboundBio, a developer of antibody-based biological therapeutics for cancers. Per the terms, Galapagos (GLPG) is expected to acq...
Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model , in partner ship with Lonza , and AboundBio ’s cutting-edge fully human antibody-based ...
Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%. Gilead's key HIV drug is beginning to feel increased competition from ViiV Healthcare's drug. T...
Mechelen, Belgium; 1 June 2022, 22 . 01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1 , Galapagos received a trans...
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...
Celebrating EULAR’s 75 th anniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium; 25 May 2022, 22 . 01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European...
Galapagos (NASDAQ:GLPG) said it exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher Medicine's Spectra platform. In August 2020, Galapagos and Scipher agreed tojointly validate a suite of IBD targets discovered by Spectra, whil...
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...